Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals develops PEDMARK, a medication to reduce platinum-induced ototoxicity in cancer patients receiving cisplatin-based chemotherapy.
SCHEDULE 13G/ANov 16Latest SEC filing
Sep 17Latest story
September 2026